Skyrocketing IPO Stock Alert: KYMERA THERAPEUTICS (NASDAQ: KYMR)

Kymera makes additional millions on more than a million shares after the successful launch of its IPO. Now NASDAQ: KYMR is reaching almost $35 by attracting many in healthcare interested investors.

By issuing the shares Kymera gets external funds for proceeding with the development of new vaccines or drugs. For some while, Kymera will get quite a long time to live on with external funding sources by showing off its cash-burn style business.

Right now Kymera is a partner with Sanofi (NASDAQ: SNY) in creating and mass manufacturing Novel Protein Degrader for treatment of patients with cancer. Funds from investors may go directly to the development of the current drug.

Jack Dawkins

Finance and Tech Contributor